7-[5-[(4-Fluorophenyl)methyl]-1,3,4-oxadiazol-2-yl]-8-hydroxy-1,6-naphthyridine-5-carbonitrile | 797787-01-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 7-[5-[(4-Fluorophenyl)methyl]-1,3,4-oxadiazol-2-yl]-8-hydroxy-1,6-naphthyridine-5-carbonitrile
• 英文别名: 7-[5-[(4-fluorophenyl)methyl]-1,3,4-oxadiazol-2-yl]-8-hydroxy-1,6-naphthyridine-5-carbonitrile
• CAS: 797787-01-0
• 化学式: C₁₈H₁₀FN₅O₂
• 分子量: 347.308
• InChiKey: KFOLFCNBUUEDPU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  109
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  7-(5-(4-fluorobenzyl)-1,3,4-oxadiazol-2-yl)-8-methoxy-1,6-naphthyridine-5-carbonitrile 在 三甲基氯硅烷 、 sodium iodide 作用下， 以 乙腈 为溶剂， 生成 7-[5-[(4-Fluorophenyl)methyl]-1,3,4-oxadiazol-2-yl]-8-hydroxy-1,6-naphthyridine-5-carbonitrile
  参考文献：
  名称：

  1,3,4-Oxadiazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 2: SAR of the C5 position

  摘要：

  The use of a 1,3,4-oxadiazole in combination with an 8-hydroxy-1,6-naphthyridine ring system has been shown to deliver potent enzyme and antiviral activity through inhibition of viral DNA integration. This report presents a detailed structure-activity investigation of the C5 position resulting in low nM potency for several analogs with an excellent therapeutic index. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.01.089

文献信息

• Naphthyridine integrase inhibitors
  申请人：Johns A. Brian

  公开号：US20070142365A1

  公开（公告）日：2007-06-21

  The present invention features compounds that are HIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.

  本发明的特点是化合物是HIV整合酶抑制剂，因此可用于抑制HIV复制，预防和/或治疗HIV感染，以及治疗艾滋病和/或ARC。
• Naphthyridine Integrase Inhibitors
  申请人：Johns Brian A

  公开号：US20110003794A1

  公开（公告）日：2011-01-06

  The present invention features compounds that are HIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.

  本发明涉及一种具有HIV整合酶抑制剂特性的化合物，因此可用于抑制HIV复制，预防和/或治疗HIV感染以及治疗艾滋病和/或ARC。
• US7812016B2
  申请人：——

  公开号：US7812016B2

  公开（公告）日：2010-10-12
• 1,3,4-Oxadiazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 2: SAR of the C5 position
  作者：Brian A. Johns、Jason G. Weatherhead、Scott H. Allen、James B. Thompson、Edward P. Garvey、Scott A. Foster、Jerry L. Jeffrey、Wayne H. Miller

  DOI：10.1016/j.bmcl.2009.01.089

  日期：2009.3

  The use of a 1,3,4-oxadiazole in combination with an 8-hydroxy-1,6-naphthyridine ring system has been shown to deliver potent enzyme and antiviral activity through inhibition of viral DNA integration. This report presents a detailed structure-activity investigation of the C5 position resulting in low nM potency for several analogs with an excellent therapeutic index. (C) 2009 Elsevier Ltd. All rights reserved.